China Pharma Holdings (CPHI) Reports Q2 Loss of $0.06
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St declines as oil prices, Treasury yields remain elevated
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Bloom Energy shares fall on Oracle project halt
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Oppenheimer sees AI software winners as focus shifts to ROI
- Arm Holdings falls as CFO stock sale weighs on sentiment
- Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
China Pharma Holdings, Inc. Reports Second Quarter Financial Results
August 12, 2016 6:00 AM EDTHAIKOU, China, Aug. 12, 2016 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE MKT: CPHI) ("China Pharma,"Â the "Company" or "We"), an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the quarter ended June 30, 2016.
Second Quarter Highlights
Revenue was $3.5 million in the second quarter of 2016, which represented a decrease of 37.6% compared to $5.7 million in the same period of 2015; Gross margin was 13.6% in the second quarter of 2016, compared to (0.98%) in the same period of 2015; Loss from... More